Top 6 Cystic fibrosis treatment startups in USA

Nov 16, 2025
|
1
Sionna Therapeutics
Funding: $292M
Sionna’s batch of small molecules will be the first to fully restore function to the cystic fibrosis transmembrane conductance regulator (CFTR) protein
2
Mediar Therapeutics
Funding: $145.6M
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
3
Stablix Therapeutics
Funding: $63M
Stablix Therapeutics, a biotechnology company pioneering the Targeted Protein Stabilization technologies that is used to cure cystic fibrosis and cancer
4
Lung Therapeutics
Funding: $53.9M
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
5
Carbon Biosciences
Funding: $38M
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
6
Deton
Funding: $1.8M
Deton is transforming the understanding and treatment of lung disease by providing complete and timely lung health information thru Aerosol Biopsy
  See also:
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com